Gain Therapeutics
GANX
GANX
25 hedge funds and large institutions have $7.68M invested in Gain Therapeutics in 2024 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
0.92% more ownership
Funds ownership: 6.56% → 7.48% (+0.92%)
21% less capital invested
Capital invested by funds: $9.77M → $7.68M (-$2.09M)
Holders
25
Holding in Top 10
–
Calls
$47K
Puts
$23K
Top Buyers
| 1 | +$198K | |
| 2 | +$181K | |
| 3 | +$118K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$101K |
| 5 |
Jones Financial Companies
Des Peres,
Missouri
|
+$96.7K |
Top Sellers
| 1 | -$4.17M | |
| 2 | -$94.8K | |
| 3 | -$9.83K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$8.62K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$8K |